Keywords: SLE; Adult; Juvenile; SLEDAI; Lupus nephritis;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Systemic lupus erythematosus; Retinal affection; SLEDAI; Anticardiolipin antibodies;
Keywords: SLE; Serum leptin; BMI; SLEDAI;
Keywords: Systemic lupus erythematosus; SLEDAI; SLICC DI; Antiphospholipid syndrome; Echocardiography;
Keywords: SLE; C4d; LN; Renal biopsy; SLEDAI;
Keywords: auto-anticorps; lupus systémique; pentraxines; rupture de tolérance; vascularite à ANCA; ANCA-associated vasculitis; auto-antibodies; pentraxins; systemic lupus; tolerance breakdown; Ac; Anticorps; ANCA; anti-neutrophil cytoplasmic antibody; BPI; Bacte
Keywords: pediatric lupus update; pediatric lupus review; lupus treatment; lupus pathogenesis; pediatric lupus; ACR; American College of Rheumatology; ANA; Antinuclear antibody; AZA; Azathioprine; cSLE; Childhood-onset systemic lupus erythematosus; CYC; Cyclophosph
Keywords: SLE; systemic lupus erythematosus; RA; rheumatoid arthritis; C3; complement factor 3; IgM, IgG; IgA immunoglobulin M, G, A; APS; antiphospholipid syndrome; anti-Ro/SSA; anti-Sjögren syndrome-related antigen A; HF; heart failure; CVD; cardiovascular disea
Keywords: Immune profile; Anti-Ro; Dyslipidemia; SLE; SLEDAI;
Keywords: Systemic lupus erythematosus; Body composition; Basal metabolic rate; SLEDAI;
Keywords: L-FABP; Lupus nephritis; Urinary markers; SLEDAI;
Keywords: AGP; α-1 acid glycoprotein; ANA; anti-nuclear antigen; AUC; area under the curve; β2MG; Beta-2-microglobulin; BILAG; British Isles Lupus Assessment Group score; C3; complement factor 3; C4; complement factor 4; CKD; chronic kidney disease patients; CrCl
Keywords: IS; immunosuppressive; AD; autoimmune disease; HIV; human immunodeficiency virus; PCP; pneumocystis pneumonia; VE; vaccine efficacy; ANCA; antineutrophil cytoplasmatic antibodies; SLE; systemic lupus erythematosus; ASIA; autoimmune inflammatory syndrome i
Keywords: CVD; cardiovascular disease; FA; fatty acyl; Fmoc; fluorenylmethoxycarbonyl; HDL; high-density lipoprotein; HNE; 4-hydroxy-2(E)-nonenal; ox-LDL; oxidized low-density lipoprotein; MDMS-SL; multi-dimensional mass spectrometry-based shotgun lipidomics; PC; c
Keywords: Staphylococcus aureus; Systemic lupus erythematosus; SLEDAI; Relapse
Keywords: Intima-media thickness; Secondary anti-phospholipid syndrome; SLE; SLEDAI
Keywords: Systemic lupus erythematosus; Major depression; SLEDAI; SLICC/ACR DI
Keywords: SLE; Ficolins; Lectin pathway; Complement; Arterial thrombosis; SLEDAI
Keywords: Urinary neutrophil gelatinase-associated lipocalin; Acute kidney injury; Systemic lupus erythematosus; Lupus nephritis; SLEDAI
Keywords: Systemic Lupus Erythematosus; Disease activity; SLEDAI; BILAG
Keywords: Lupus nephritis; Lymphopenia; SLE; SLEDAI; SLICC/DI
Silent cerebral MRI findings in lupus nephritis patients: Is it clinically significant?
Keywords: Lupus nephritis; Asymptomatic cerebral MRI lesions; White matter hyperintense lesions; SLEDAI;
Spectrum of clinical manifestations of SLE patients from India and its correlation with KIR gene polymorphism
Keywords: SLE; systemic lupus erythematosus; MHC; major histocompatibility complex; KIR; the killer cell immunoglobulin-like receptor; NK; natural killer; ANA; anti-nuclear autoantibodies; ACR; American College of Rheumatology; SLICC; Systemic Lupus International
Clinical significance of tumor necrosis factor-α-863 C/A and -1031 T/C promoter polymorphisms in systemic lupus erythematosus patients: Relation to disease activity and damage
Keywords: TNF-α; -863C/A, -1031T/C; Promoter polymorphism; Systemic lupus erythematosus; SLEDAI;
Role of glutathione S-transferases polymorphisms and monocyte CD64 expression in Egyptian patients with systemic lupus erythematosus
Keywords: GSTM1; GSTT1; GSTP1 polymorphisms; Monocyte CD64; SLE; SLEDAI; SLICC damage index;
IL22 in Egyptian SLE patients, could it reflect disease activity, skin or renal involvement or is it only an expensive ESR?
Keywords: IL22; SLE; Th22; SLEDAI; Lupus nephritis;
Clinical significance of vitamin D deficiency and receptor gene polymorphism in systemic lupus erythematosus patients
Keywords: SLE; Vitamin D; VDR FokI and BsmI polymorphism; SLEDAI; Damage index;
Juvenile systemic lupus erythematosus (jSLE): Auditory pathway affection in relation to disease activity
Keywords: Juvenile systemic lupus erythematosus (jSLE); Cognitive function; SLEDAI; Disease activity; Mismatch negativity;
The role of interleukin-17A in the pathogenesis of kidney diseases
Keywords: Interleukin-17A; inflammation; kidney disease; AHR; aryl hydrocarbon receptor; AKI; acute kidney injury; ANCA; antineutrophil cytoplasmic antibody; APOE; apolipoprotein E; ASC; apoptosis-associated speck-like protein containing a carboxy-terminal CARD; Ct
Increased soluble CD72 in systemic lupus erythematosus is in association with disease activity and lupus nephritis
Keywords: BCR; B cell receptor; SLE; systemic lupus erythematosus; sCD72; soluble CD72; SLEDAI; SLE disease activity; dsDNA; double-stranded DNA; aCL; anti-cardiolipin Ab; Breg; B regulatory; Treg; T regulatory cells; ITIM; immune receptor tyrosine-based inhibition
Association between anti-Ro 60 kDa (SS-A) autoantibodies and hypocomplementemia in systemic lupus erythematosus patients from Algiers prefectures
Keywords: Anti SSA; Circulating immune complexes; Classical pathway of complement; Systemic lupus erythematosus; SLEDAI
MicroRNA-21, microRNA-181a and microRNA-196a as potential biomarkers in adult Egyptian patients with systemic lupus erythematosus
Keywords: SLE; SLEDAI; miR-21; miR-181a; miR-196a;
Correlation of QT interval with disease activity in newly detected SLE patients at baseline and during flare
Keywords: SLE; QT interval; disease activity; SLEDAI; flare;
Comparison of high versus low–medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis
Keywords: Systemic lupus erythematosus; Methyl-prednisolone; Glucocorticoids; Avascular osteonecrosis; Osteoporosis; Diabetes mellitus; Cataracts; Activity; SLEDAI; Damage
Magnetic resonance imaging (MRI) brain abnormalities of neuropsychiatric systemic lupus erythematosus patients in Mansoura city: Relation to disease activity
Keywords: Magnetic resonance imaging (MRI); Systemic lupus erythematosus; Neuropsychiatric; Brain abnormalities; SLEDAI
Anti-nucleosome antibodies: A potential surrogate marker for renal affection in lupus patients with insignificant proteinuria
Keywords: Anti-nucleosome antibodies; SLE; Lupus nephritis; SLEDAI
Serum BLyS and APRIL as possible indicators of disease activity in pediatric systemic lupus erythematosus and juvenile idiopathic arthritis
Keywords: Pediatric SLE; SLEDAI; JIA; JADAS-27; BLyS; APRIL
A T cell gene expression panel for the diagnosis and monitoring of disease activity in patients with systemic lupus erythematosus
Keywords: SLE; systemic lupus erythematosus; RA; rheumatoid arthritis; SLEDAI; systemic lupus erythematosus disease activity index; BILAG; British Isles lupus assessment group; qPCR; real time polymerase chain reaction; CART; classification and regression trees; CM
Th1/Th2 cytokine profile in childhood-onset systemic lupus erythematosus
Keywords: Interferon gamma (IFN-γ); Tumor necrosis factor alpha (TNF-α); Interleukin (IL) 5, 6, 10, and 12; SLEDAI; Childhood-onset systemic lupus erythematosus;
Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients
Keywords: dsDNA; double-stranded DNA; SLE; systemic lupus erythematosus; SLEDAI; SLE Disease Activity Index; Anti-CD38 autoantibodies; CD38; Cytokine profiles; IL-10; Systemic lupus erythematosus;
Comparison of three anti-dsDNA assays: Performance and correlation with systemic lupus erythematosus disease activity
Keywords: Anti-DNA antibodies; BioPlex; Farr assay; Farrzyme; Nephritis; SLEDAI; Systemic lupus erythematosus
Invasive fungal infection in patients with systemic lupus erythematosus: Experience from a single institute of Northern China
Keywords: IFI; invasive fungal infection; SLE; systemic lupus erythematosus; CRP; C reactive protein; ESR; erythrocyte sedimentation rate; SLEDAI; systemic lupus erythematosus disease activity index; EORTC/MSG; European Organization for Research and Treatment of Ca
Shrinking lung syndrome in systemic lupus erythematosus patients with dyspnea
Keywords: Systemic lupus erythematosus; Shrinking lung syndrome; Dyspnea; SLEDAI; SLICC
High-sensitivity C-reactive protein (hs-CRP) in systemic lupus erythematosus patients without cardiac involvement; relation to disease activity, damage and intima-media thickness
Keywords: High sensitivity C-reactive protein (hs-CRP); Systemic lupus erythematosus (SLE); SLEDAI; SLICC; Intima-media thickness (IMT)
Systemic lupus erythematosusDifferences in Autoantibody Profiles and Disease Activity and Damage Scores Between Childhood- and Adult-Onset Systemic Lupus Erythematosus: A Meta-Analysis
Keywords: SLE (lupus; systemic lupus erythematosus); adult; pediatric; differences; autoantibodies; SLE disease activity; SLEDAI; SLE damage index (SLICC SDI);
Serum BAFF level and its correlations with various disease parameters in patients with systemic sclerosis and systemic lupus erythematosus
Keywords: Systemic lupus erythematosus; Systemic sclerosis; BAFF; MRSS; SLEDAI; SLICC
Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers
Keywords: Mechanism of action; Rheumatoid arthritis; Systemic lupus erythematosus; Sjögren's syndrome; Biomarker; B cell-targeting drugs; ACPA; anti-citrullinated peptide antibody; ACR; American College of Rheumatology; APRIL; a proliferation-inducing ligand; BCMA
Tibolone in postmenopausal women with systemic lupus erythematosus: A pilot study
Keywords: Tibolone; Postmenopause; Systemic lupus erythematosus; Hormone replacement therapy; SLEDAI; Vasomotor symptoms